Tribute Pharmaceuticals Canada Inc (SLRXF) financial statements (2022 and earlier)

Company profile

Business Address 544 EGERTON ST
LONDON, ON N5W 3Z8
State of Incorp. ON
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3,5062,8132,284
Cash and cash equivalents3,5062,8132,284
Receivables2,1455921,205
Inventory, net of allowances, customer advances and progress billings1,0371,0451,001
Inventory1,0371,0451,001
Prepaid expense180141
Deferred costs12891 
Prepaid expense and other current assets119
Other undisclosed current assets153693277
Total current assets:7,1505,3754,886
Noncurrent Assets
Property, plant and equipment1,0121,0901,159
Intangible assets, net (including goodwill)44,55813,31614,482
Goodwill3,5993,5993,599
Intangible assets, net (excluding goodwill)40,9599,71710,883
Other undisclosed noncurrent assets359254301
Total noncurrent assets:45,92914,66015,943
TOTAL ASSETS:53,08020,03520,829
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:4,3453,2855,456
Other undisclosed accounts payable and accrued liabilities4,3453,2855,456
Debt1,3192051,306
Derivative instruments and hedges, liabilities3,1082,967202
Other undisclosed current liabilities 38(202)
Total current liabilities:8,7726,4946,762
Noncurrent Liabilities
Long-term debt and lease obligation13,9675,6401,816
Long-term debt, excluding current maturities13,9675,6401,816
Liabilities, other than long-term debt  315
Deferred tax liabilities, net  315
Other undisclosed noncurrent liabilities  202
Total noncurrent liabilities:13,9675,6402,333
Total liabilities:22,73912,1349,094
Stockholders' equity
Stockholders' equity attributable to parent30,3417,90011,734
Common stock41,18319,94717,590
Additional paid in capital2,7142,2871,868
Accumulated other comprehensive loss (38) 
Accumulated deficit(19,903)(14,296)(7,724)
Warrants and rights outstanding6,347  
Total stockholders' equity:30,3417,90011,734
TOTAL LIABILITIES AND EQUITY:53,08020,03520,829

Income statement (P&L) ($ in thousands)

12/31/2014
12/31/2013
12/31/2012
Revenues16,87213,44012,343
Revenue, net16,90913,83612,343
Cost of revenue
(Cost of Goods and Services Sold)
(1,788)(1,542)(1,221)
Other undisclosed gross profit(5,955)(5,901)(5,953)
Gross profit:9,1295,9975,169
Operating expenses(11,661)(11,076)(9,590)
Operating loss:(2,532)(5,079)(4,421)
Nonoperating income (expense)
(Investment Income, Nonoperating)
(168)(399)247
Interest and debt expense(1,442)(527)(147)
Net loss:(4,141)(6,005)(4,320)
Other undisclosed net income (loss) attributable to parent(1,466)(567)971
Net loss available to common stockholders, diluted:(5,607)(6,572)(3,349)

Comprehensive Income ($ in thousands)

12/31/2014
12/31/2013
12/31/2012
Net loss:(4,141)(6,005)(4,320)
Comprehensive loss:(4,141)(6,005)(4,320)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1,466)(567)971
Comprehensive loss, net of tax, attributable to parent:(5,607)(6,572)(3,349)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: